CD8A and neoplasm: While GSK-3β inhibition during the priming phase may enhance dendritic cell activation, cross-presentation, and primary CD8 T-cell effector responses to improve early tumor control, sustained inhibition may be detrimental to the development and maintenance of memory T cells.